This inventor holds 2 USPTO granted patents. Top assignee: University of California. Active years: 2006-2007.
Company Filing History:
Years Active: 2006-2007
Title: Innovations of Inventor Günter Harth
Introduction
Günter Harth is a notable inventor based in Los Angeles, CA. He has made significant contributions to the field of immunology through his innovative patents. With a total of 2 patents, Harth's work focuses on the development of vaccines utilizing abundant extracellular products from pathogens.
Latest Patents
Harth's latest patents include groundbreaking methods for producing vaccines based on one or more combinations of majorly abundant extracellular products of pathogens. These vaccines are designed to stimulate a protective immune response in mammalian hosts against subsequent infections by the target pathogen. The selection of these extracellular products is made irrespective of their absolute molecular immunogenicity. They can be characterized and distinguished by their respective N-terminal amino acid, amino acid, or DNA sequences. The versatility of these vaccines allows for various combinations of extracellular products, subunits, or encoding nucleic acids, providing a broad range of effective immunotherapeutic compositions. Additionally, these vaccines can be utilized to stimulate an effective immune response against intracellular pathogens.
Career Highlights
Günter Harth is affiliated with the University of California, where he continues to advance his research and innovations in the field of vaccine development. His work has the potential to significantly impact public health by providing new methods for combating infectious diseases.
Collaborations
Harth has collaborated with esteemed colleagues such as Marcus Aaron Horwitz and Bai-Yu Lee, contributing to the advancement of his research and the development of innovative solutions in immunology.
Conclusion
Günter Harth's contributions to vaccine development through his innovative patents highlight the importance of research in combating infectious diseases. His work exemplifies the potential of utilizing abundant extracellular products to create effective immunotherapeutic compositions.